keyword
MENU ▼
Read by QxMD icon Read
search

Statin and vitamin d insufficiency

keyword
https://www.readbyqxmd.com/read/27717074/different-cardiometabolic-effects-of-atorvastatin-in-men-with-normal-vitamin-d-status-and-vitamin-d-insufficiency
#1
Robert Krysiak, Małgorzata Gilowska, Bogusław Okopień
BACKGROUND: Vitamin D is suggested to reduce cardiovascular risk. HYPOTHESIS: Circulating levels of plasma lipids and other cardiovascular risk factors may differ between statin-treated patients with different vitamin D status. METHODS: We studied 3 age- and weight-matched groups of men with elevated low-density lipoprotein cholesterol (LDL-C) levels: vitamin D-naïve men with vitamin D insufficiency (group A, n = 18), men with vitamin D deficiency/insufficiency effectively treated with vitamin D preparations (group B, n = 16), and vitamin D-naïve men with normal vitamin D status (group C, n = 16)...
September 26, 2016: Clinical Cardiology
https://www.readbyqxmd.com/read/25496224/vitamin-k-and-other-markers-of-micronutrient-status-in-morbidly-obese-patients-before-bariatric-surgery
#2
M Ewang-Emukowhate, D J Harrington, A Botha, B McGowan, A S Wierzbicki
BACKGROUND: Micronutrient deficiencies occur in morbidly obese patients. The aim of this study was to assess vitamin deficiencies prior to bariatric surgery including vitamin K about which there is little data in this population. METHODS: A prospective assessment of 118 consecutive patients was performed. Clinical allied with haematological and biochemical variables were measured. Micronutrients measured included vitamins K1 , PIVKA-II (protein-induced in vitamin K absence factor II), vitamin D, vitamin B12 (holotranscobalamin), iron, transferrin and folate...
June 2015: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/24742497/low-vitamin-d-as-a-risk-factor-for-the-development-of-myalgia-in-patients-taking-high-dose-simvastatin-a-retrospective-review
#3
Kari Mergenhagen, Michael Ott, Kerry Heckman, Lisa M Rubin, Kenneth Kellick
BACKGROUND: Statins are the treatment of choice for dyslipidemia, primarily lowering elevated LDL-C levels and reducing the occurrence of major cardiovascular events. In June 2011, the Food and Drug Administration issued a warning regarding the use of high-dose simvastatin 80 mg and its risk of myopathy. OBJECTIVE: The incidence of myalgia, myopathy, and rhabdomyolysis was analyzed in a veteran population prescribed simvastatin 80 mg. Risk factors for myalgia were examined and compared with the results of recently published studies...
May 2014: Clinical Therapeutics
https://www.readbyqxmd.com/read/24423442/medication-among-patients-with-type-1-diabetes-and-predialytic-renal-disease
#4
Jaakko Helve, Reijo Sund, Mikko Haapio, Per-Henrik Groop, Carola Grönhagen-Riska, Patrik Finne
AIMS: To examine use and changes of medication in the three years before start of chronic renal replacement therapy (RRT) among patients with type 1 diabetes, and the association between predialytic medication and survival on RRT. METHODS: We recorded medication of 496 patients with type 1 diabetes before and after start of RRT in 2000-2006 and followed up until death or end of 2009. Data were retrieved from the Finnish Registry for Kidney Diseases and from the FinDM diabetes database...
March 2014: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/24158983/nurse-practitioner-care-improves-renal-outcome-in-patients-with-ckd
#5
RANDOMIZED CONTROLLED TRIAL
Mieke J Peeters, Arjan D van Zuilen, Jan A J G van den Brand, Michiel L Bots, Marjolijn van Buren, Marc A G J Ten Dam, Karin A H Kaasjager, Gerry Ligtenberg, Yvo W J Sijpkens, Henk E Sluiter, Peter J G van de Ven, Gerald Vervoort, Louis-Jean Vleming, Peter J Blankestijn, Jack F M Wetzels
Treatment goals for patients with CKD are often unrealized for many reasons, but support by nurse practitioners may improve risk factor levels in these patients. Here, we analyzed renal endpoints of the Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of Nurse Practitioners (MASTERPLAN) study after extended follow-up to determine whether strict implementation of current CKD guidelines through the aid of nurse practitioners improves renal outcome. In total, 788 patients with moderate to severe CKD were randomized to receive nurse practitioner support added to physician care (intervention group) or physician care alone (control group)...
February 2014: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/23802504/novel-drugs-and-intervention-strategies-for-the-treatment-of-chronic-kidney-disease
#6
REVIEW
Hiddo Jan Lambers Heerspink, Dick de Zeeuw
Chronic kidney disease (CKD) is a worldwide health problem. The disease is most often progressive of nature with a high impact on patients and society. It is increasingly recognized that CKD can be detected in the early stages and should be managed as early as possible. Treatment of the cause, but in particular control of the main risk markers, such as high blood pressure, glucose and albuminuria, has been instrumental in delaying the progression to end-stage renal disease (ESRD). However, despite the state of the art therapy, the absolute risk of renal and cardiovascular morbidity and mortality in CKD patients remains devastatingly high...
October 2013: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/23737732/pathogenesis-and-novel-treatment-from-the-mouse-model-of-type-2-diabetic-nephropathy
#7
REVIEW
Masako Furukawa, Tomohito Gohda, Mitsuo Tanimoto, Yasuhiko Tomino
Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease worldwide. However, current treatments remain suboptimal. Many factors, such as genetic and nongenetic promoters, hypertension, hyperglycemia, the accumulation of advanced glycation end products (AGEs), dyslipidemia, and albuminuria/proteinuria itself, influence the progression of this disease. It is important to determine the molecular mechanisms and treatment of this disease. The development of diabetes results in the formation of AGEs, oxidative stress, and the activation of the renin-angiotensin-aldosterone system (RAAS) within the kidney, which promotes progressive inflammation and fibrosis, leading to DN and declining renal function...
2013: TheScientificWorldJournal
https://www.readbyqxmd.com/read/23262496/25-hydroxyvitamin-d-insufficiency-is-associated-with-impaired-renal-endothelial-function-and-both-are-improved-with-rosuvastatin-treatment
#8
RANDOMIZED CONTROLLED TRIAL
Christian Ott, Ulrike Raff, Markus P Schneider, Stephanie I Titze, Roland E Schmieder
BACKGROUND: Vitamin D deficiency is nowadays considered as a potential cardiovascular and renal risk factor. We tested the hypotheses that vitamin D deficiency impairs the endothelial function of renal vasculature and whether vitamin D levels and endothelial function can be improved by the treatment with statins. METHODS: In a double-blind, randomized study of 31 hypercholesterolemic patients with vitamin D insufficiency (<30 ng/ml) were randomly assigned to rosuvastatin (10 mg/d) and placebo for 6 weeks...
April 2013: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/22980306/vitamin-d-levels-do-not-predict-cardiovascular-events-in-statin-treated-patients-with-stable-coronary-disease
#9
RANDOMIZED CONTROLLED TRIAL
Vera Bittner, Nanette K Wenger, David D Waters, David A DeMicco, Michael Messig, John C LaRosa
BACKGROUND: This post hoc nested case-control analysis of the TNT study was designed to investigate whether baseline vitamin D level is a significant predictor of cardiovascular risk among statin-treated patients and whether changes in vitamin D after treatment with atorvastatin are associated with improved cardiovascular outcomes. METHODS: A total of 10,001 patients with stable coronary heart disease were randomized to atorvastatin 80 or 10 mg for a median of 4...
September 2012: American Heart Journal
https://www.readbyqxmd.com/read/22739979/multifactorial-intervention-with-nurse-practitioners-does-not-change-cardiovascular-outcomes-in-patients-with-chronic-kidney-disease
#10
RANDOMIZED CONTROLLED TRIAL
Arjan D van Zuilen, Michiel L Bots, Arzu Dulger, Ingeborg van der Tweel, Marjolijn van Buren, Marc A G J Ten Dam, Karin A H Kaasjager, Gerry Ligtenberg, Yvo W J Sijpkens, Henk E Sluiter, Peter J G van de Ven, Gerald Vervoort, Louis-Jean Vleming, Peter J Blankestijn, Jack F M Wetzels
Strict implementation of guidelines directed at multiple targets reduces vascular risk in diabetic patients. Whether this also applies to patients with chronic kidney disease (CKD) is uncertain. To evaluate this, the MASTERPLAN Study randomized 788 patients with CKD (estimated GFR 20-70 ml/min) to receive additional intensive nurse practitioner support (the intervention group) or nephrologist care (the control group). The primary end point was a composite of myocardial infarction, stroke, or cardiovascular death...
September 2012: Kidney International
https://www.readbyqxmd.com/read/22302254/strategies-to-preserve-the-use-of-statins-in-patients-with-previous-muscular-adverse-effects
#11
REVIEW
Kurt M Reinhart, J Andrew Woods
PURPOSE: The published evidence on strategies for avoiding the discontinuation of statin therapy due to muscular adverse effects is reviewed. SUMMARY: Statin medications are a cornerstone of the prevention and treatment of coronary heart disease, but about 20% of treated patients develop myalgia or other muscle-related adverse effects that can lead to the discontinuation of statin use. As there are no consensus guidelines or firm practice recommendations on continuing or reinitiating statin therapy in patients who experience statin-related muscular adverse effects, a literature search was conducted to evaluate a variety of strategies that have been studied...
February 15, 2012: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/20817794/atorvastatin-increases-25-hydroxy-vitamin-d-concentrations-in-patients-with-polycystic-ovary-syndrome
#12
RANDOMIZED CONTROLLED TRIAL
Thozhukat Sathyapalan, John Shepherd, Charlotte Arnett, Anne-Marie Coady, Eric S Kilpatrick, Stephen L Atkin
BACKGROUND: It has been shown that many women with polycystic ovary syndrome (PCOS) are 25-hydroxyvitamin D (25OHD) insufficient. Both statin treatment and vitamin D supplementation have been shown to improve biochemical hyperandrogenemia, insulin resistance, and markers of inflammation in patients with PCOS, raising the possibility that some of the statin effects are mediated through vitamin D. METHODS: We conducted this randomized, double-blind placebo controlled study to assess the effect of atorvastatin on serum 25OHD concentrations in patients with PCOS...
November 2010: Clinical Chemistry
https://www.readbyqxmd.com/read/19424034/achieving-chronic-kidney-disease-treatment-targets-in-renal-transplant-recipients-results-from-a-cross-sectional-study-in-spain
#13
MULTICENTER STUDY
Roberto Marcén, Domingo del Castillo, Luis Capdevila, Gema Fernandez-Fresnedo, Emilio Rodrigo, Carmen Cantarell, Ana Fernández-Rodriguez, María O López-Oliva, Joaquin Camps, Pedro Aljama, Joaquín Ortuño, Manuel Arias
BACKGROUND: Kidney transplant recipients are considered to have chronic kidney disease (CKD) irrespective of glomerular filtration rate (GFR) or presence or absence of markers of kidney damage. The aim of this work was to investigate the prevalence of CKD-stages and whether the guidelines for general population (Kidney Disease Outcomes Quality Initiative) are routinely followed in kidney transplant in Spain. PATIENTS AND METHODS: Two thousand one hundred sixty renal transplant recipients followed up at the outpatient clinics in 4 University Hospitals were included...
May 15, 2009: Transplantation
https://www.readbyqxmd.com/read/19287183/statins-do-not-affect-mineral-metabolism-in-chronic-kidney-disease-a-retrospective-analysis
#14
Neil Ashman, Anindya Banerjee, Muhammad M Yaqoob
It has recently been proposed that statins act as vitamin D analogs in binding the ubiquitously expressed vitamin D receptor, accounting for the perceived pleiotropic effects of statins (a reduction in cancer risk, prevention of organ transplant rejection and autoimmune disease). Chronic kidney disease (CKD) offers a useful test of this hypothesis: serum 25-hydroxyvitamin D levels are insufficient (<75 nmol/l) in as many as 76% of patients with advanced CKD, associated with secondary hyperparathyroidism and reduced bone mineralization...
2009: Nephron. Clinical Practice
https://www.readbyqxmd.com/read/18941372/chemoprevention-of-colorectal-cancer-feasibility-in-everyday-practice
#15
REVIEW
László Herszényi, Fabio Farinati, Pál Miheller, Zsolt Tulassay
Chemoprevention means the use of agents to prevent, delay, or reverse carcinogenesis. This review was designed to critically discuss the most promising agents in colorectal cancer (CRC) chemoprevention. Aspirin is the best studied chemopreventive agent for CRC. Optimal chemoprevention requires long-term use and high dose of aspirin that may increase the risk of gastrointestinal bleeding. Nonsteroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors may also be candidates for chemoprevention...
November 2008: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/12911045/efficacy-and-safety-of-plant-stanols-and-sterols-in-the-management-of-blood-cholesterol-levels
#16
REVIEW
Martijn B Katan, Scott M Grundy, Peter Jones, Malcolm Law, Tatu Miettinen, Rodolfo Paoletti et al.
Foods with plant stanol or sterol esters lower serum cholesterol levels. We summarize the deliberations of 32 experts on the efficacy and safety of sterols and stanols. A meta-analysis of 41 trials showed that intake of 2 g/d of stanols or sterols reduced low-density lipoprotein (LDL) by 10%; higher intakes added little. Efficacy is similar for sterols and stanols, but the food form may substantially affect LDL reduction. Effects are additive with diet or drug interventions: eating foods low in saturated fat and cholesterol and high in stanols or sterols can reduce LDL by 20%; adding sterols or stanols to statin medication is more effective than doubling the statin dose...
August 2003: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/12695727/diagnosis-and-therapy-of-coronary-artery-disease-in-renal-failure-end-stage-renal-disease-and-renal-transplant-populations
#17
REVIEW
Christine M Logar, Charles A Herzog, Srinivasan Beddhu
Even though cardiovascular disease is the leading cause of death in patients with CRF and end-stage renal disease (ESRD), ill-conceived notions have led to therapeutic nihilism as the predominant strategy in the management of cardiovascular disease in these populations. The recent data clearly support the application of proven interventions in the general population, such as angiotensin-converting enzyme inhibitors and statins to patients with CRF and ESRD. The advances in coronary stents and intracoronary irradiation have decreased the restenosis rates in renal failure patients...
April 2003: American Journal of the Medical Sciences
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"